Product description
Fast delivery and high quality Liraglutide CAS NO.204656-20-2 with best price
| Product Name: |
Liraglutide |
| CAS: |
204656-20-2 |
| MF: |
C172H265N43O51 |
| MW: |
3751.202 |
| EINECS: |
810-818-7 |
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes.
Functions&Applications:
Medical Uses
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 Diabetes
Liraglutide improves control of blood glucose. Delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
About us
Hebei Lingding Biotechnology Co., Ltd. is a professional business company ,that include pharmaceutical raw materials, pharmaceutical intermediates,and other more than 1000 products of the enterprise, The registered capital is 3 million yuan, it is a collection of scientific research, production and sales in one of the enterprises.
Since its establishment, the company has always adhered to the core concept of "focus on products, attentive service", adhere to the business purpose of "innovation, professional, win-win", to provide customers with a full range of meticulous and thoughtful services. We will adhere to the customers serious and responsible attitude, comply with the standardized operation procedures, with efficient execution to complete customer needs.
The company's products are sold all over the world, mainly exported to the United States, Europe, Southeast Asia, Australia, the Middle East and South Africa and other countries.The company has a strong scientific research and technical team, can provide customers with high quality products and a full range of services. We will provide firstclass products and better service to face the needs of customers, to meet the challenges of the market. Welcome domestic and foreign customers to negotiate.
Packaging & Shipping
| Shipping Terms |
| By Express |
By Air |
By Sea |
Suitable for under 50kg
Fast: 3-7 days
Door to door service,
easy to pick up the goods |
Suitable for more than 50kg
Fast: 3-7 days
High cost
Port to port,
professional broker needed |
Suitable for more than 500kg
Slow: 7-45 days
Low cost
Port to port,
professional broker needed |
Our Advantage
Audited Supplier 
){kind=link}
){kind=link}